Following the rejection of the AstraZeneca COVID-19 vaccines, the country has express its readiness to share same with needy African countries.
This was made known by a senior official, as a medical association said the first shots from rival Johnson & Johnson could arrive the country, on Tuesday.
Recall that the country paused the rollout of AstraZeneca doses earlier this month after preliminary trial data showed they offered minimal protection against mild to moderate illness from the country’s dominant coronavirus variant.
The government had since been consulting with scientists about what to do with the AstraZeneca vaccine, switching to a plan to start inoculating healthcare workers with J&J’s alternative in a research study.
The South African Medical Association (SAMA) said if the first shots arrived, on Tuesday, as expected, then vaccinations could start, on Wednesday.
Eighty thousand J&J shots are expected initially, and up to 500,000 health workers could be immunised in total in the study.
SAMA chairwoman, Angelique Coetzee, said vaccinations would happen at hospitals in each of the country’s nine provinces. Roughly two-thirds of the doses would go to public-sector health workers, and one-third to those in the private sector.
Anban Pillay, deputy director-general at the Department of Health, said South Africa planned to share the 1 million AstraZeneca doses it received at the start of the month from the Serum Institute of India via the African Union (AU).
“The doses are going to be shared with countries on the continent … via the AU,” Pillay told Reuters, adding that the government would look to recover money spent on the AstraZeneca vaccine but was still finalising how to do that.
He said it was not true that South Africa had asked the Serum Institute to take back the doses, as reported by Indian newspaper The Economic Times.
The AU’s disease control body said last week it was not ‘walking away’ from AstraZeneca’s vaccine but would target its use in countries that have not reported cases of the more contagious 501Y.V2 variant first identified in South Africa late last year.
The AU said six countries other than South Africa had confirmed the variant was circulating, but there are concerns it has spread elsewhere.
AstraZeneca said it believed its two-dose vaccine protects against severe COVID-19 and that it has started adapting it to be more effective against the 501Y.V2 variant. J&J’s vaccine is administered in a single shot, an advantage given how complex a logistical exercise it will be for the government to reach its target of vaccinating 40 million people.
SPUTNIK DOCUMENTATION
South Africa’s health ministry said the manufacturers of Russia’s Sputnik V vaccine had submitted documentation to local medicines regulator SAHPRA for registration.
The ministry said it was “continuously engaging” with the manufacturers of Sputnik V and that it had signed a non-disclosure agreement with China’s Sinopharm to receive more information about its vaccine.
It added that scientists were conducting detailed analyses on Sputnik V, following concerns about the effects of its Ad5 component on communities with a high prevalence of HIV.
South Africa has one of the highest HIV burdens globally.
SAHPRA did not immediately respond to a request for comment.
COVID-19: S’ Africa to Share ‘Rejected’ AstraZeneca Vaccine, as First J&J Shots Expected
